364 related articles for article (PubMed ID: 17366602)
1. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
2. Overexpression through amplification of genes in chromosome region 17p11.2 approximately p12 in high-grade osteosarcoma.
van Dartel M; Redeker S; Bras J; Kool M; Hulsebos TJ
Cancer Genet Cytogenet; 2004 Jul; 152(1):8-14. PubMed ID: 15193436
[TBL] [Abstract][Full Text] [Related]
3. Amplification and overexpression of genes in 17p11.2 ~ p12 in osteosarcoma.
van Dartel M; Hulsebos TJ
Cancer Genet Cytogenet; 2004 Aug; 153(1):77-80. PubMed ID: 15325100
[TBL] [Abstract][Full Text] [Related]
4. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma.
Onda M; Matsuda S; Higaki S; Iijima T; Fukushima J; Yokokura A; Kojima T; Horiuchi H; Kurokawa T; Yamamoto T
Cancer; 1996 Jan; 77(1):71-8. PubMed ID: 8630943
[TBL] [Abstract][Full Text] [Related]
5. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization.
Kresse SH; Ohnstad HO; Paulsen EB; Bjerkehagen B; Szuhai K; Serra M; Schaefer KL; Myklebost O; Meza-Zepeda LA
Genes Chromosomes Cancer; 2009 Aug; 48(8):679-93. PubMed ID: 19441093
[TBL] [Abstract][Full Text] [Related]
6. Mutation spectrum of p53 gene in highly malignant human osteosarcomas.
Radig K; Schneider-Stock R; Oda Y; Neumann W; Mittler U; Roessner A
Gen Diagn Pathol; 1996 Jun; 142(1):25-32. PubMed ID: 8793483
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
8. Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation.
Henriksen J; Aagesen TH; Maelandsmo GM; Lothe RA; Myklebost O; Forus A
Oncogene; 2003 Aug; 22(34):5358-61. PubMed ID: 12917637
[TBL] [Abstract][Full Text] [Related]
9. Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.
McHugh JB; Thomas DG; Herman JM; Ray ME; Baker LH; Adsay NV; Rabah R; Lucas DR
Cancer; 2006 Aug; 107(3):554-62. PubMed ID: 16795069
[TBL] [Abstract][Full Text] [Related]
10. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
11. The expression of CRM1 is associated with prognosis in human osteosarcoma.
Yao Y; Dong Y; Lin F; Zhao H; Shen Z; Chen P; Sun YJ; Tang LN; Zheng SE
Oncol Rep; 2009 Jan; 21(1):229-35. PubMed ID: 19082467
[TBL] [Abstract][Full Text] [Related]
12. Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma.
Wang Z; Cai H; Lin L; Tang M; Cai H
Pediatr Blood Cancer; 2014 Feb; 61(2):206-10. PubMed ID: 24038809
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
[TBL] [Abstract][Full Text] [Related]
14. SAS is amplified predominantly in surface osteosarcoma.
Noble-Topham SE; Burrow SR; Eppert K; Kandel RA; Meltzer PS; Bell RS; Andrulis IL
J Orthop Res; 1996 Sep; 14(5):700-5. PubMed ID: 8893761
[TBL] [Abstract][Full Text] [Related]
15. Comparative genomic hybridization of low-grade central osteosarcoma.
Tarkkanen M; Böhling T; Gamberi G; Ragazzini P; Benassi MS; Kivioja A; Kallio P; Elomaa I; Picci P; Knuutila S
Mod Pathol; 1998 May; 11(5):421-6. PubMed ID: 9619593
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
Park HR; Min K; Kim HS; Jung WW; Park YK
Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723
[TBL] [Abstract][Full Text] [Related]
17. Sporadic amplification of the MYC gene in human osteosarcomas.
Ladanyi M; Park CK; Lewis R; Jhanwar SC; Healey JH; Huvos AG
Diagn Mol Pathol; 1993 Sep; 2(3):163-7. PubMed ID: 8287230
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
[TBL] [Abstract][Full Text] [Related]
19. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas.
Entz-Werlé N; Marcellin L; Gaub MP; Guerin E; Schneider A; Berard-Marec P; Kalifa C; Brugiere L; Pacquement H; Schmitt C; Tabone MD; Jeanne-Pasquier C; Terrier P; Dijoud F; Oudet P; Lutz P; Babin-Boilletot A
J Clin Oncol; 2005 Apr; 23(10):2248-55. PubMed ID: 15800315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
